Jul. 15 at 10:11 PM
$GOSS $PYPD @Finnish_boy @HROWfan @StockScubaDiver Check this out PYPD just announced this am the development of a long-acting GLP-1 receptor agonist delivery platform capable of maintaining therapeutic levels for approximately 60 days from a single subcutaneous administration – potentially reducing injections from weekly to just six times yearly. (They have less than a 40m market cap ) Recent
$870 Million Deal Validates Exactly What PolyPid Just Unveiled.
The timing couldn’t be more striking. Just days ago, Eli Lilly announced a collaboration worth up to
$870 million with Sweden’s Camurus to develop long-acting formulations of their incretin drugs. This follows Novo Nordisk’s
$285 million deal with Ascendis Pharma for once-monthly GLP-1 technology last November. Read this article too. I doubled my shaes this am on news and it was actuallt down a nickel aand closed up. https://the10xradar.substack.com/p/polypid-the-biotech-that-broke-my
